Skip to main content

Table 7 Influence of different combined oral contraceptive formulations in the lipid concentrations of polycystic ovary syndrome

From: Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

COC formulation

Number of studies

Before

Md (1st – 3rd)

After

Md (1st – 3rd)

∆

p*

Total Cholesterol (mg/dl)

 EE 35 μg / CPA 2 mg

12

173.7 (162.1–184.1)

189.0 (185.3–200.9)

+15.3

0.012

 EE 30 μg / DRSP 3 mg

09

171.5 (166.8–185.9)

185.2 (167.3–203.1)

13.7

0.085

 EE 30 μg / DSG 75–150 μg

03

158.9 (154.9–162.9)

178.8 (169.0–188.4)

+19.5

0.108

 EE 30 μg / 180–250 μg NGM

02

168.9 (167.6–170.2)

181.7 (181.3–182.1)

+12.8

0.060

 EE 30 μg / 150 μg LNG

02

161.8 (158.4–165.2)

170.4 (169.1–173.8)

+8.6

0.265

LDL-C (mg/dl)

 EE 35 μg / CPA 2 mg

11

98.0 (91.0–103.9)

101.9 (86.8–114.6)

+3.9

0.241

 EE 30 μg / DRSP 3 mg

08

95.2 (87.6–107.0)

101.3 (92.6–113.1)

+6.1

0.345

 EE 30 μg / CMA 2 μg

03

101.5 (99.6–103.4)

100.9 (98.3–103.5)

+0.6

0.486

 EE 30 μg / DSG 75–150 μg

03

94.3 (94.0–94.5)

106.8 (100.9–112.7)

+12.5

0.108

 EE 30 μg / NGM 180–250 μg

02

100.2 (99.9–100.5)

107.6 (106.7–108.3)

+7.4

0.031

 EE 30 μg / LNG 150 μg

02

87.2 (77.4–97.0)

90.6 (80.2–101.0)

+3.4

0.022

HDL-C (mg/dl)

 EE 35 μg / CPA 2 mg

10

54.3 (50.2–59.5)

61.5 (60.7–67.2)

+7.3

0.020

 EE 30 μg / DRSP 3 mg

08

59.5 (50.0–62.5)

73.3 (64.5–79.7)

+13.8

0.017

 EE 30 μg / CMA 2 mg

03

51.1 (49.9–52.3)

61.4 (61.1–61.7)

+10.3

0.108

 EE 30 μg / DSG 75/150 μg

03

49.6 (34.7–59.7)

45.3 (26.0–75.0)

−3.3

0.592

TG (mg/dl)

 EE 35 μg / CPA 2 mg

11

81.4 (69.0–99.1)

104.0 (85.8–123.4)

+22.6

0.021

 EE 30 μg / DRSP 3 mg

07

95.0 (72.8–105.6)

116.8 (115.0–138.9)

+21.8

0.017

 EE 30 μg / CMA 2 mg

03

83.9 (83.6–84.2)

125.5 (116.1–134.9)

+41.6

0.108

 EE 30 μg / DSG 75–150 μg

03

87.7 (83.7–91.7)

108.3 (102.4–114.2)

+20.6

0.137

 EE 30 μg / NGM 180–250 μg

03

104.7 (86.1–123.3)

134.3 (117.4–151.3)

+29.6

0.025

  1. COC combined oral contraceptive, Md (1st – 3rd) median, first and third quartiles, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglyceride, CPA cyproterone acetate, DRSP drospirenone, CMA chlormadinona acetate, DSG desogestrel, NGM norgestimate, LNG levonorgestrel
  2. p* Wilcoxon signed- ranks test